English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18054/20253 (89%)
Visitors : 24244170      Online Users : 465
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/32594

    標題: Effect of Bronchodilator and Steroid Use on Heart Disease and Stroke Risks in a Bronchiectasis-Chronic Obstructive Pulmonary Disease Overlap Cohort: A Propensity Score Matching Study
    作者: Yeh, Jun-Jun(葉俊濬)
    Yang, Yu-Cih
    Hsu, Chung Y.
    Kao, Chia-Hung
    貢獻者: Chia Yi Christian Hosp, Dept Famiy Med, Ditmanson Med Fdn
    Chia Nan Univ Pharm & Sci, Dept Early Childhood Educ & Nursery
    China Med Univ, Coll Med
    China Med Univ Hosp, Management Off Hlth Data
    China Med Univ, Grad Inst Biomed Sci, Coll Med
    China Med Univ, Sch Med, Coll Med
    China Med Univ Hosp, Dept Nucl Med
    Asia Univ, Dept Bioinformat & Med Engn
    China Med Univ Hosp, Ctr Augmented Intelligence Healthcare
    關鍵字: heart disease
    bronchiectasis-chronic obstructive pulmonary disease overlap syndrome
    日期: 2019-11
    上傳時間: 2020-07-29 13:51:17 (UTC+8)
    摘要: Background: To determine the effects of bronchodilator, steroid, and anti-arrhythmia drug use on the risk of heart disease/stroke (HDS) in patients with bronchiectasis-chronic obstructive pulmonary disease overlap syndrome (BCOS). Methods: We retrospectively enrolled patients with BCOS (BCOS cohort, n = 1,493) and patients without bronchiectasis and chronic obstructive pulmonary disease (COPD) (non-BCOS cohort, n = 5,972). The cumulative incidence of HDS was analyzed through Cox proportional regression. We calculated adjusted hazard ratios (aHRs) and their 95% confidence intervals (CIs) for HDS after adjustments for sex, age, comorbidities, long-acting beta 2-agonist or long-acting muscarinic antagonist (LABAs/LAMAs) use, short-acting beta 2-agonist or short-acting muscarinic antagonist (SABAs/SAMAs) use, oral steroid (OSs) or inhaled corticosteroid steroid (ICSs) use, and anti-arrhythmia drugs use. Results: The aHR (95% CI) for HDS was 1.08 (0.28-4.06) for patients using LAMAs compared with those not using drugs. Regarding drug use days, the aHRs (95% CIs) were 32.2 (1.79-773.0), 1.85 (1.01-3.39), and 31.1 (3.25-297.80) for those with recent SABAs use, past ICSs use, and past anti-arrythmia drugs use, respectively. Regarding cumulative drug dose, the aHRs (95% CIs) were 2.12 (1.46-3.10), 3.48 (1.13-10.6), 3.19 (2.04-4.99), 28.1 (1.42-555.7), 2.09 (1.32-3.29), 2.28 (1.53-3.40), and 1.93 (1.36-2.74) for those with a low dose of SABAs, medium dose of SABAs, low dose of SAMAs, low dose of ICSs, medium dose of ICSs, low dose of OSs, and medium dose of OSs, respectively. Conclusions: Compared with patients without bronchiectasis and COPD, BCOS patients with recent SABAs, past ICSs, and past anti-arrhythmia drugs use; a low or medium SABAs ICSs, and OSs dose; and a low SAMAs dose had a higher risk of HDS. LAMAs were not associated with HDS.
    關聯: Frontiers in Pharmacology, v.10, 1409
    Appears in Collections:[嬰幼兒保育系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    10.3389-fphar.2019.01409.pdf923KbAdobe PDF392View/Open

    All items in CNU IR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback